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A functional ORF-A is essential for efficient feline immunodeficiency virus replication in lymphocytes. We have charac-
terized a series of mutants of the Petaluma strain, derived from p34TF10 and having different combinations of stop codons
and increasingly long deletions in ORF-A. Six clones proved fully replicative in fibroblastoid Crandell feline kidney cells and
monocyte-derived macrophage cultures but failed to replicate in T cell lines and primary lymphoblasts. Cats inoculated with
three selected mutants had considerably milder infections than controls given intact ORF-A virus. In vivo, the mutants
maintained growth properties similar to those in vitro for at least 7 months, except that replication in lymphoid cells was
strongly reduced but not ablated. One mutant underwent extensive ORF-A changes without, however, reverting to wild-type.
Antiviral immune responses were feeble in all cats, suggesting that viral loads were too low to represent a sufficientlyINTRODUCTION
Although no practically useful products have been
obtained as yet, the development of vaccines against
human immunodeficiency virus (HIV) has progressed
using several animal models (D’Souza et al., 2000; Levy,
2001; Lewis and Babiuk, 1999; Nathanson and Mathie-
son, 2000). In the feline immunodeficiency virus (FIV)
model, attempts have included the use of whole inacti-
vated virus vaccines, both cell-free and cell-associated
(Bishop et al., 1996; Hosie et al., 1995, 2000; Matteucci et
al., 1996, 1999; Pu et al., 2001; Yamamoto et al., 1993),
subunit vaccines (Finerty et al., 2000; Huisman et al.,
1998; Leutenegger et al., 1998; Lombardi et al., 1994;
Richardson et al., 1998; Siebelink et al., 1995), DNA vac-
cines (Boretti et al., 2000; Cuisinier et al., 1997; Hosie et
al., 1998; Richardson et al., 1997), and attenuated vac-
cines administered either as infectious virus (Pistello et
al., 1999a) or as proviral DNA (Lockridge et al., 2000), but
the results have been generally disappointing.
One of the best strategies for developing stably atten-
uated vaccines consists of silencing specific regions of
the viral genome dispensable for virus replication but
important for full pathogenic potential (Nathanson and
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84Mathieson, 2000). Desrosiers and his group pioneered
by altering accessory genes of simian immunodeficiency
virus (SIV) (see Daniel et al., 1992; Desrosiers et al., 1998;
Johnson et al., 1999; Wyand et al., 1999), and subse-
quently the soundness of this approach has also been
confirmed by other groups (reviewed in Almond and
Stott, 1999) and indirectly substantiated by the finding
that certain HIV-infected individuals who have not devel-
oped disease after many years may have deletions in
their infecting HIV (Alexander et al., 2000; Brambilla et al.,
1999; Rhodes et al., 2000).
Accessory genes of FIV include vif, ORF-A (also called
ORF2), and rev. Recently, Lockridge et al. (2000) reported
that inoculation with infectious proviral DNA of a vif-
deletion mutant of the PPR strain of FIV protected cats
from challenge with homologous virus. Vif functions at a
late stage of the virus cycle and is critical for cell-
free virus infectivity (Inoshima et al., 1998; Shacklett and
Luciw, 1994; Tomonaga et al., 1993). The product of the
ORF-A gene is believed to represent a viral transactivator
and has functions reminiscent of the Tat protein in other
lentiviruses (Bigornia et al., 2001; de Parseval and Elder,
1999). Furthermore, truncation between the leucine-rich
and cysteine-rich domains of ORF-A was shown to pre-
serve in vitro replication of FIV in fibroblasts but to
greatly restrict virus replication in cultured feline lym-
phoid cells (Tomonaga et al., 1993; Waters et al., 1996)
and in peripheral blood mononuclear cells (PBMC) of
infected specific-pathogen-free (SPF) cats (Dean et al.,powerful antigenic stimulus. © 2002 Elsevier Science (USA)
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1999; Norway et al., 2001). We reasoned that such prop-
erties might be useful in the preparation of attenuatedtants;
vaccines because (1) decreased virus replication in lym-
phocytes was likely to spare these cells from depletion
and prevent clinical immunosuppression with its possible
consequences also on responsiveness to the vaccine virus
and (2) unimpaired virus replication in other cell typesmight
continuously produce an antigenic mass sufficient to create
a robust, long-lasting protective immunity.
With this in mind, we produced and characterized a
series of molecular clones of FIV, which carried different
combinations of stop codons and deletions downstream
of the leucine-rich region of ORF-A, i.e., in the same
region as the mutants studied by Waters et al. (1996), and
were therefore likely to have replication properties in line
with such a rationale. In vitro, most of our mutants grew
normally or near normally in fibroblastoid cells and mac-
rophages but produced no detectable infectious virus in
lymphoid cells. Inoculation of selected mutants into SPF
cats showed similar growth properties for at least 7
months, except that replication in lymphoid cells was
markedly reduced but not abolished. Interestingly, one
mutant underwent rapid and extensive ORF-A changes in
vivo without, however, reverting to wild-type. The antiviral
immune responses mounted by infected cats were fee-
ble, suggesting that the infections produced by the
ORF-A mutants were too mild to generate a powerful
antigenic stimulus.
RESULTS
ORF-A mutants studied
During preparation, one construct (p-210) was found
to be highly unstable and was excluded from further
studies. A total of 11 plasmids were thus studied (Fig. 1).
These included the following: (1) the parental molecular
clone p34TF10 (hereafter designated p-10), which con-
tains the whole genome of the Petaluma strain of FIV
(FIV-Pet) and had a premature stop codon in place of the
tryptophan codon present in wild-type virus at ORF-A
nucleotide (nt) position 6120 (referred to Talbott et al.,
1989), as already reported by Phillips and colleagues
(1992); (2) 9 derivatives, produced and designated as
indicated under Materials and Methods, which had one
or two stop codons and/or 3-, 7-, or 10-amino-acid (aa)-
long deletions in the ORF-A gene; and (3) a control
having an intact ORF-A and obtained by replacing the
stop codon of p34TF10 with a tryptophan codon (p-00).
FIG. 1. Modifications introduced in ORF-A. (A) Location of ORF-A in the FIV provirus. The overlapping ORF-B and -C found in FIV-Pet but not in other
FIV strains are also shown. (B) Predicted ORF-A protein with the domains present also in the corresponding protein (Tat) of other lentiviruses
(Tomonaga and Mikami, 1996) shown as shaded areas. (C) Location of the stop codon present in the parental p34TF10. (D) Mutations introduced in
this plasmid for producing the clones studied. Asterisks and dashes represent stop codons and amino acid deletions, respectively.
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Growth properties in vitro
The above plasmids were tested for replication com-
petence by transfection into Crandell feline kidney (CrFK)
cell cultures and monitoring for markers of FIV produc-
tion biweekly for up to 5 weeks (Table 1). The cultures
transfected with p-07, p-010, p-110, p-23, p-27, the
parental p-10, and the control wild-type p-00 devel-
oped characteristic FIV-induced syncytia starting 2 days
after transfection and, from day 4 onward, released de-
tectable infectious virus in the supernatant. Consistent
with previous reports that the ORF-A gene is dispensable
for FIV replication in CrFK cells (Dean et al., 1999; Waters
et al., 1996), kinetics and levels of progeny virus produc-
tion by these plasmids were similar, regardless of
whether their ORF-A was intact or truncated. In contrast,
plasmids p-03, p-13, p-17, and p-20 generated no
detectable infectious FIV throughout the observation pe-
riod, even though some transfected CrFK cell cultures
developed syncytia or transitorily tested reverse tran-
scriptase (RT)-PCR-positive.
Cell-free viral clones generated in such transfections
(designated v-xy) were compared for the ability to rep-
licate in primary lymphoblasts obtained from the PBMC
of noninfected cats, in T lymphoid cells of the interleukin
(IL)-2-dependent lines MBM and AP32, and, as a control,
in CrFK cells. As expected, the control clone v-00 grew
with good efficiency in all such cells. In contrast, the
ORF-A mutated clones grew with comparable efficien-
cies in CrFK cells but failed to replicate productively in all
the lymphoid cultures tested. More precisely, following
inoculation with the latter clones, primary lymphoblasts
remained uniformly virus-negative by all parameters ex-
amined, and certain MBM and AP32 cell supernatants
were FIV RNA- and p25-positive but contained no detect-
able FIV infectivity, as determined in fresh lymphoblasts
and CrFK cells, possibly as a result of minimal or abor-
tive viral replication as the in vivo findings discussed
below might suggest (Table 2). Because we had difficul-
ties in maintaining feline monocyte-derived macro-
phages (MDM) in culture for protracted periods, the
ability of clones to replicate in these cells was investi-
gated by measuring how many proviral copies accumu-
lated in inoculated cultures during the first 4 days of
incubation. Preliminary experiments had shown that, fol-
lowing inoculation with the wild-type ORF-A clone v-00,
provirus copy numbers associated with MDM at this time
were on average 60-fold higher than detected immedi-
ately after the inoculum. As shown in Table 2, the ORF-
A-defective clones accumulated substantial levels of
provirus, although these were variously reduced relative
to the control clone.
Mutated viruses were also evaluated for genetic sta-
bility in vitro by sequencing their ORF-A genes after
propagation in CrFK cells for a minimum of 2 months.
Since no changes relative to input clones were observed
(data not shown), all were considered suitable for in vivo
inoculation.
Growth properties in vivo
The in vitro findings had shown that v-07, v-010,
v-110, v-23, and v-27 had an essentially unimpaired
ability to grow in fibroblastoid CrFK cells and MDM but
were unable to replicate productively in lymphoid cells.
Three such clones were selected for in vivo studies
based on the partially different behaviors exhibited in
vitro: in particular, they had shown high (v-07), interme-
diate (v-110), or poor growth activities in MDM (v-23)
or had differed with regard to the release of FIV RNA and
p25 in the supernatant of inoculated lymphoid cell lines
(Table 2). Stocks of these clones and control wild-type
TABLE 1
Virological Markers in CrFK Cells Transfected with Molecular Clones of FIV Carrying Different ORF-A Mutationsa
Plasmid clone Syncytia FIV-RNA RT p25
Infectivity of supernatant
for CrFK cells
p-00 (control) 3b 6b 0.294c 0.980c 
p-10 (parental) 3 5 0.239 0.870 
p-03 2 —d — — 
p-07 2 4 0.763 2.441 
p-010 2 4 0.797 2.5 
p-13 2 — — — 
p-17 — 7 — — 
p-110 5 5 0.103 0.969 
p-20 — — — — 
p-23 5 5 0.220 1.786 
p-27 2 5 0.798 2.5 
a Results of one representative experiment out of three performed.
b Supernatants were tested for viral genomes by RT-PCR. Number of days when the cultures first became positive.
c Supernatants were tested for RT activity and p25 antigen by ELISA. Absorbance values obtained 2 days posttransfection.
d (—) Negative after 35 days of culture.
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v-00 were titrated in CrFK cells, checked for the pres-
ence of the proper ORF-A sequence, and injected sub-
cutaneously into groups of six SPF cats at 400 50% tissue
culture infectious doses/cat.
The outcomes of cat inoculation were examined at 0.5,
1, 3, 5, and 7 months. All animals remained clinically
healthy but became FIV-positive, as demonstrated by the
presence of varied levels of viral RNA in plasma and/or
proviral DNA in PBMC. By 2 weeks postinfection only 2/6,
1/6, and 3/6 animals in groups 07, 110, and 23 were
plasma viremia-positive, respectively, versus 6/6 group
00 cats. Furthermore, all animals inoculated with ORF-A
mutated clones had peaks of plasma viremia markedly
lower than v-00 (Fig. 2). Cocultivation of scaled num-
bers of freshly harvested total PBMC with MBM cells
demonstrated generally low numbers of infectious virus-
producing units (range 1–102 units/106 PBMC) in all in-
jected cats throughout the study period but these were
uniformly fewer in 07, 110, and 23 cats than in 00
animals (data not shown). It was thus clear that all three
ORF-A truncated clones studied had a greatly reduced
virulence for cats, compared to intact virus.
The cell type supporting replication in vivo of the three
ORF-A mutated clones was investigated by separating by
adherence lymphocytes and MDM from the PBMC of
infected cats and measuring the provirus copy numbers
present in such cells. As shown in Fig. 3, the lympho-
cytes of control group 00 started to become provirus-
positive at 0.5 months and showed substantial loads by
1 month, peak levels at 3 months (range 1303 to 5980
copies per microgram of genomic DNA, average 3321),
and considerably declined levels at later sampling
points, thus in essence paralleling plasma viremia kinet-
ics in the same animals (Fig. 2). The peripheral lympho-
cytes of cats inoculated with ORF-A mutants also proved
FIV DNA-positive at one or more sampling points; how-
ever, their involvement was modest, as shown by gener-
ally very low proviral burdens and delayed peaks. The
only exception was cat 3132 in group 23, who at 5 and
7 months had substantial proviral loads. Figure 3 also
shows the proviral copy numbers present in purified
MDM. Consistent with the in vitro results, at all times
tested the MDM of control 00 cats showed low proviral
loads compared to the corresponding lymphocytes. Im-
portantly, however, cats infected with ORF-A truncated
viruses had levels of MDM-associated provirus in the
same range as control cats, despite the highly reduced
plasma viremia and lymphocyte-associated proviral
loads discussed above. Thus, collectively these findings
showed that, in infected cats, the representative ORF-A
mutants studied replicated at a normal rate in cells of the
macrophage lineage and very inefficiently in lympho-
cytes, albeit in vivo the dichotomy between the two cell
types was less pronounced than observed under in vitro
conditions.
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Genetic stability in vivo
To evaluate the in vivo stability of ORF-A in the mu-
tants, we directly amplified and sequenced the region of
interest from the virus present in plasma at 1, 3, and 7
months postinfection, from the provirus detected in pu-
rified lymphocytes and MDM at 7 months (all cats), and
from viruses reisolated from cultured PBMC (selected
cats). All sequences from groups 00, 070, and 23,
including that from cat 3132 discussed above, were iden-
tical to the respective input viruses (data not shown). In
contrast, the ORF-A of v-110 proved extremely unstable,
as shown by early development of nonsynonymous mu-
tations and occasional deletions (Table 3). Interestingly,
one cat in this group (No. 3078) harbored the same
ORF-A sequence in plasma and MDM and a distinct one
in lymphocytes, possibly indicating that, in this animal,
the majority of virus in plasma was not lymphocyte-
derived. Of note, while the virus samples reisolated in
culture from the other groups had homogeneous ORF-A
sequences, those obtained from 110 cats contained
multiple ORF-A variants, which were essentially similar
to those described above, although sometimes they pre-
sented larger deletions, generally located downstream of
the stop codon (data not shown).
Anti-FIV immune responses of inoculated cats
The anti-FIV immune responses produced by inocu-
lated cats were evaluated by measuring ELISA antibod-
ies and lymphoproliferative responses to disrupted
whole virus at all sampling points. Except in two cats
inoculated with v-00, antiviral antibodies developed
slowly and remained low in titer throughout the obser-
vation period (Fig. 4). Lymphoproliferation levels were
only sporadically above the threshold value, with little or
no differences among groups (Fig. 5). CD4 and CD8 T
lymphocyte counts, performed at 5 and 7 months postin-
fection, showed no significant deviations compared to
age-matched, control SPF cats (data not shown), thus
confirming the poor pathogenicity of p34TF10-derived
FIV-Pet (Dean et al., 1999).
DISCUSSION
Despite extremely interesting results in SIV (Almond
and Stott, 1999; Joag et al., 1998; Johnson et al., 1999;
Nixon et al., 2000; Wyand et al., 1999) and encouraging
premises also in FIV (Bigornia et al., 2000; Lockridge et
al., 2000; Pistello et al., 1999a), attenuated viruses have
thus far received little attention as candidate FIV vac-
cines. The present study was prompted by findings by
Waters et al. (1996) that an intact ORF-A is required for
productive FIV replication in lymphocytes although it is
dispensable for growth in other cell types. We reasoned
that virus still competent for growth in other cells but
stably restricted in its ability to replicate in lymphocytes
might persist in infected hosts without grossly impairing
their immune capabilities, thus proving valuable for the
development of attenuated vaccines. To test this con-
cept, we mutagenized the FIV-Pet genome of p34TF10
FIG. 2. Plasma viremia levels in cats inoculated with wild-type (group 00) or ORF-A mutated virus clones (groups 07, 110, and 23). Virus RNA
was quantitated by RT-TM-PCR. Asterisks indicate statistically significant differences between the mean values of groups inoculated with ORF-A
mutants versus group 00 (*P  0.05; **P  0.01).
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and produced several mutants which, due to the pres-
ence of one or two stop codons and/or one variously
large deletion within the accessory gene ORF-A, were
increasingly unlikely to undergo reversion to wild-type,
an event observed in nef mutants of SIV (Carl et al., 1999;
Whatmore et al., 1995), and impacted differently onto the
overlapping ORF-B and -C (Talbott et al., 1989). The last
two ORFs have been predicted in some FIV isolates only
and have no recognized gene product (de Parseval and
Elder, 1999; Tomonaga et al., 1995; Tomonaga and Mi-
kami, 1996), yet the possibility could not be excluded a
priori that their inactivation conferred unwanted charac-
teristics onto the mutants.
During preparation of the viral clones, we met with two
difficult to explain findings. The first was that four ORF-A
mutated plasmids consistently failed to give rise to virus
progeny in transfected fibroblastoid CrFK cells, thus sug-
gesting that certain ORF-A mutations might be detrimen-
tal for productive FIV infection of these cells. This might
indicate that ORF-B and -C are somehow involved in
FIV-Pet replication in these cells or, more likely, that
secondary structure and/or stability of several mRNAs
which contain the ORF-A segment (de Parseval and El-
der, 1999; Tomonaga et al., 1995; Tomonaga and Mikami,
1996) may have been differently affected by different
ORF-A mutations. The second unexpected finding was
that, among the viral mutants having no stop codons, one
that carried a short deletion (03) proved replication-
incompetent, whereas two mutants with longer deletions
(07 and 010) replicated with good efficiency in both
CrFK cells and MDM. As determined by the PDH pro-
gram (ExPaSy), the predicted secondary structures of the
truncated ORF-A proteins encoded by the three clones
did not appear to be grossly disrupted; however, model-
ing studies based on crystallographic data would be
necessary to exclude subtle conformational changes. It
has been previously demonstrated that the truncated
ORF-A protein encoded by p34TF10 has lost the ability to
transactivate (de Parseval and Elder, 1999; Waters et al.,
1996). Although no chloramphenicol acetyl transferase
assay was performed with our clones, it is conceivable
that differently mutated ORF-A proteins transactivate with
varying efficiency. Further studies will be required to
precisely define the functional motifs of the ORF-A prod-
uct of FIV and how they were affected by the changes
introduced into our mutants.
The growth properties of six mutated ORF-A clones
that could be expanded in CrFK cells were investigated
in vitro and in vivo. In vitro characterization essentially
confirmed previous data (Dean et al., 1999; Waters et al.,
1996) in that, although the six clones replicated in CrFK
cells as efficiently as the intact clone, none produced
infectious virus when inoculated into cultured lymphoid
cells. Furthermore, in cultured MDM the ORF-A mutated
clones accumulated provirus copy numbers only slightly
reduced relative to the control clone, suggesting that an
intact ORF-A is not essential for FIV replication in in vitro
grown macrophages.
Cat inoculation studies assessed in vivo infectivity and
virulence, extent of replication in lymphocytes and MDM,
and genetic stability of three ORF-A mutants that had
exhibited partially divergent properties in vitro, namely,
v-07, v-10, and v-23. Anti-FIV immune responses
mounted by infected cats were also investigated. With
regard to the first two aspects, our results confirmed and
extended previous findings by Sparger et al. (1994), Ino-
shima et al. (1996), Dean et al. (1999), and Norway et al.
(2001), in that all animals became unequivocally infected,
regardless of the mutated clone inoculated, but with one
exception had levels of plasma viremia, proviral loads in
PBMC, and infectious circulating cells much reduced
compared to those in parallel animals injected with virus
having an intact ORF-A. In previous studies (Sparger et
al., 1994; Dean et al., 1999), a clone apparently identical
to our v-10 had replicated even less efficiently in cats,
most likely due to the lower virus dose and different route
FIG. 3. Proviral loads in peripheral lymphocytes and MDM of cats
inoculated with wild-type (group 00) or ORF-A mutated virus clones
(groups 07, 110, and 23). Proviral DNA was quantitated by TM-PCR.
Asterisks as in Fig. 2.
89CHARACTERIZATION OF FIV ORF-A MUTANTS
used for infection. In this context, it is worth noting that
our viral clones did not probably permit a full appraisal of
the extent of attenuation associated with ORF-A disrup-
tion since they were derived from p34TF10 virus, which
has repeatedly been shown to be poorly virulent (Dean et
al., 1999; Sparger et al., 1994). All such clones readily
infected CrFK cells, and this deviation from the behavior
of recent clinical FIV isolates is known to correlate with
reduced in vivo virulence (Barlough et al., 1993; Dean et
al., 1999; Hosie et al., 2000; Pistello et al., 1999a,b). It
seems therefore likely that the differential observed in
the degree of virulence between ORF-A truncated and
wild-type clones would have been greater if the clones
had been prepared starting from fully virulent virus.
The MDM of inoculated cats were found to be uni-
formly provirus-positive at loads similar to those de-
TABLE 3
Changes Observed in the ORF-A Sequence of v-110 during Infection of SPF Cats
Cat
Plasma virus at month postinoculation
Lymphocyte provirusa MDM provirusa1 3 7
484 TGT to TATb TGT to TAT TGT to TAT TGT to TAT TGT to TAT
3078 NAc TGT to TAT TGT to TAT Deletion of 18 aad TGT to TAT
3089 TGT to TAT NA TGT to TAT TGT to TAT TGT to TAT
3114 TGTTTA to TATATAe TGT to TAT Two variants:
(a) deletion of 52 aa; f
(b) 110 plus a downstream
deletion of 19 aag
NA Two variants:
(a) deletion of 52 aa; f
(b) 110 plus a downstream
deletion of 19 aag
3119 TGT to TAT NA TGT to TAT TGT to TAT TGT to TAT
3153 NA TGT to TAT NA TGT to TAT NA
a Proviral sequences checked at 7 months.
b Nonsynonymous mutation at nt position 6157 (aa change cysteine to tyrosine).
c NA, not amplifiable.
d The original 110 deletion (nt 6126 to 6155) was extended up to nt 6180.
e Nonsynonymous mutations at nt 6157 and 6159 (aa changes cysteine to tyrosine and leucine to isoleucine, respectively).
f Deletion from nt 6084 to 6204, causing complete removal of the original 110 region.
g Downstream deletion from nt 6184 to 6241, removing the 3-end of ORF-A and the genomic region between ORF-A and env.
FIG. 4. ELISA antibody titers to whole FIV in cats inoculated with wild-type (group 00) or ORF-A mutated virus clones (groups 07, 110, and 23).
Titers are expressed as the reciprocal of the highest serum dilution that gave optical density readings at least threefold higher than the mean of 10
naive cat sera.
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tected in wild-type virus-infected cats, thus corroborating
previous results showing that feline macrophages sup-
port FIV replication in vivo (Dean et al., 1999; Dow et al.,
1992, 1999; English et al., 1993). Lymphocytes of the
same cats also tested provirus-positive but at copy num-
bers that, except in one cat, were reduced 100-fold or
more compared to control virus-infected cats, thus indi-
cating that the inability of the ORF-A mutants to replicate
in lymphocytes was not as absolute in vivo as it had
appeared in vitro. A discrepancy between in vitro and in
vivo behavior of wild-type and ORF-A defective FIV was
noted also by Norway et al. (2001) and might reflect the
larger spectrum of lymphoid cell types and subtypes
available for virus replication in vivo. For example, in
infected cats FIV has been shown to undergo substantial
replication in B cells (Dean et al., 1996; English et al.,
1993; Woo et al., 1997), a cell type poorly represented in
the lymphoid cultures that were used for characterizing
the clones in vitro. On the other hand, the observation in
this and previous studies (Sparger et al., 1994; Norway et
al., 2001) that the PBMC of cats infected with ORF-A-
defective clones readily yielded infectious virus when
cocultured with lymphoid T cells might be indicative that
in vivo these mutants reacquire a certain ability to grow
in lymphocytes. Propagation of the PPR strain of FIV in
IL-2-independent T cells was recently seen to widen the
spectrum of cell types that supported its replication, and
this effect correlated with mutations in the env gene
(Lerner and Elder, 2000).
Stability of the ORF-A mutations was evaluated at
completion of cat follow-up as well as at two earlier
times. Two clones (v-07 and v-23) proved as stable as
they had been after 2 months in cultured cells. In con-
trast, v-110, which also had remained unchanged in
vitro, rapidly developed additional ORF-A mutations and
deletions in all infected cats for reasons that have re-
mained elusive. We found no changes in the long termi-
nal repeats of the variants emerged (data not shown),
thus excluding the possibility that ORF-A instability might
be triggered by concomitant mutation of the target for the
ORF-A protein (de Parseval and Elder, 1999). In any case,
even this highly unstable clone showed no tendency to
revert to wild-type ORF-A, suggesting that FIV is under
little pressure for reacquisition of a normal ORF-A in vivo
as in vitro.
In contrast with previous findings (Dean et al., 1999;
Sparger et al., 1994), in the present study all cats inocu-
lated with ORF-A truncated viruses seroconverted, as
determined by ELISA against disrupted whole FIV anti-
gen. The antibody responses evoked were, however,
weak and delayed relative to control cats inoculated with
intact ORF-A virus. Importantly, even the latter responded
feebly, possibly as a consequence of the reduced viru-
lence of p34TF10 virus discussed above, a feature that
may also explain why lymphocyte subset counts were
not affected by infection. FIV-specific lymphoproliferative
activity was also modest in all groups at all times tested.
In summary, these findings demonstrate the feasibility
of developing genetically stable ORF-A defective mutants
of FIV that are impaired for replication in lymphocytes but
grow normally or near normally in other cell types, both
in vitro and in vivo. That cats infected with such mutants
mounted rather poor immune responses does not herald
well for their direct use as candidate attenuated FIV
vaccines. Conclusions about this aspect must, however,
await the results of the challenge experiments currently
under way.
MATERIALS AND METHODS
Construction of mutants
All mutants were generated from the recombinant
plasmid p34TF10 (GenBank Accession Nos. M25381 and
FIG. 5. Lymphoproliferative response to whole FIV in cats inoculated
with wild-type (group 00) or ORF-A mutated virus clones (groups 23,
07, and 110). The dotted line marks stimulation index  2, which was
considered the cut-off value. Absence of columns denotes test not done.
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NC_001482 in its revised version), kindly provided by Dr.
J. H. Elder (The Scripps Research Institute, La Jolla, CA).
p34TF10 was digested enzymatically by using BspMII (nt
position of the restriction site 5397) and KpnI (6396), and
the fragment thus obtained was filled in and subcloned
into the EcoRV-linearized BlueScript plasmid. Site-spe-
cific mutagenesis of ORF-A was carried out on this con-
struct by inverse PCR with the proofreading Expand High
Fidelity DNA polymerase (Roche Diagnostics, Basel,
Switzerland) and 25 cycles only, to prevent unwanted
mutations during the amplification step. The primers
used are available from the authors upon request. Mu-
tagenized fragments were then reinserted into the
p34TF10 backbone. Proper insertion and absence of
unwanted mutations were assessed by sequencing the
entire region at each step. Plasmids were designated
p-xy, where x indicates the number of stop codons (0,
1, or 2) and y the number (0, 3, 7, or 10) of deleted amino
acids.
Transfections and progeny viral stocks
Transfection of the plasmids in CrFK cells was carried
out by the calcium phosphate method. Supernatants with
high RT activity were pooled and used to produce prog-
eny viral stocks of the replication-competent clones (des-
ignated v-xy), which were titered by measuring RT
activity.
Cell cultures
Primary lymphoblasts and MDM were obtained by
culturing freshly harvested, Ficoll-Paque gradient-puri-
fied PBMC pooled from normal SPF cats at 2  106
cells/ml in RPMI 1640 medium containing 10% fetal bo-
vine serum (FBS), 5 g/ml concanavalin A (Con A;
Sigma–Aldrich, Milan, Italy), and 10 U/ml recombinant
human IL2 (Roche Diagnostics, Monza, Italy). After 24 h,
the nonadherent cells were removed, cultured in the
same medium, and used as a source of primary lympho-
blasts while the adherent cells were washed three times
with phosphate-buffered saline, pH 7.5, fed with RPMI
1640 containing 10% FBS, and used as a source of MDM.
Fibroblastoid CrFK cells and IL2-dependent T lymphoid
cell lines MBM (Matteucci et al., 1995) and AP32 (Maz-
zetti et al., 1999) were propagated using the routine
procedures of our laboratory. Viral inocula were normal-
ized by RT optical density. In the case of MDM, the
cultures were stopped 4 days later and virus production
was monitored by TM-PCR alone due to low numbers of
cells. All other cultures were monitored by testing the
supernatant fluids for RT activity, p25 antigen (Mazzetti et
al., 1999), and viral RNA for at least 5 weeks.
Animals
Ten-month-old female SPF cats were purchased at
IFFA Credo (L’Arsbresle, France) and housed in our in-
fectious disease isolation facility under European Com-
munity law conditions. Inoculations were carried out sub-
cutaneously. All animals were physically examined for
clinical signs daily and bled for serological, hematolog-
ical, and virus detection assays immediately prior to
virus inoculation and at selected times thereafter.
Plasma viremia measurement
Plasma was extracted with the QIAamp Viral RNA kit
(Qiagen, Milan, Italy), and RNA was reverse-transcribed
with 900 nM antisense primer PU8-AS TGAATAATCTTC-
CTTAGCTCCTTGTCT (1467–1493), as described (Pistello
et al., 1999a). cDNA was amplified by TM-PCR on the ABI
Prism 7700 Sequence Detection System instrument (Per-
kin–Elmer/Applied Biosystems, Monza, Italy) with the
Universal PCR Master Mix (Perkin–Elmer/Applied Bio-
systems), 900 nM sense primer PU8-S CACCAGCTAG-
GATGCAGTGTAGA (nt position 1375–1397), and 200 nM
probe PU8-P TTGGCTGCCATAAAAGCTAAGTCTCCTCG
(1425–1453). Amplification was carried out in 50 l by the
default cycle, except that the number of cycles was 50 to
increase sensitivity. Samples and controls (negative and
positive) were tested in duplicate and in triplicate, re-
spectively, and a few no-template controls were also
interspersed randomly in each amplification plate. Serial
10-fold dilutions of gag p24 RNA transcripts were used to
produce a standard curve. Intra- and interassay preci-
sion and reproducibility of the assay were assessed as
described (Leutenegger et al., 1999; Pistello et al., 2001).
The sensitivity of the assay was 200 copies/ml plasma,
as evaluated by extracting and amplifying FIV-negative
plasma spiked with serial 10-fold dilutions of pGEM-Pet
RNA transcripts.
Proviral load quantitation
Genomic DNA was extracted from cells using the
QIAamp DNA Blood Mini Kit (Qiagen). In the case of
MDM, the cells were extracted directly in the culture
wells. Extracted DNA (0.2–0.6 g) was tested for com-
petence for amplification as described (Cammarota et
al., 1996), and provirus DNA was quantitated by TM-PCR
under the conditions described above, except that the
reaction volume was 25 l. Serial 10-fold dilutions (101 to
107) of p34TF10 in a background of 1 g of genomic DNA
were used to produce a standard curve and determine
the lowest limit of detection (10 copies).
ORF-A sequencing
Amplification was carried out by hemi-nested PCR,
using the following primers: first step, ORFA-FI 5-AAA-
GACTCGCTATGTTGGCGT-3 (nt position 5839–5859) and
V12AS 5-TTGCTCTTCTAAACTTACCTGC-3 (6522–6500);
second step, ORFA-FII 5-AGTGGCGAGGATGCTGTA-
ATCA-3 (5877–5899) and V12AS. Virus RNA was re-
verse-transcribed with the antisense primer (V12AS)
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prior to amplification. Amplified products were checked
by agarose gel electrophoresis and, whenever a single
amplicon was present, directly analyzed by cycle se-
quencing using the 237AS primer 5-CCAGGTACCCTA-
AATGGGTTTACTCCT-3 and the automated ALF DNA
sequencer (Amersham Pharmacia Biotech, Cologno
Monzese, Italy). If multiple amplicons were detected by
agarose gel, they were separated either by cutting gel
slices or touching each band with a tip or needle. Sep-
arated fragments were then reamplified with the inner
primers, electrophoresed, and, in the presence of a sin-
gle band, sequenced. Each sample was amplified and
sequenced twice on different occasions. Sequences
were then aligned and compared and, if they were dis-
cordant, the whole amplification and sequencing pro-
cess was repeated.
Qualitative and semiquantitative virus isolation
Ficoll-purified PBMC (106) were Con A stimulated and
cocultured with MBM cells, and culture supernatants
were monitored biweekly for p25 and RT production for
up to 5 weeks. Enumeration of circulating FIV producing
cells was performed by cocultivating 10-fold serial dilu-
tions of PBMC with MBM cells and monitoring as for the
qualitative assay.
Miscellaneous assays
Anti-FIV antibodies were tested by ELISA against son-
icated whole FIV-Pet as described (Mazzetti et al., 1999).
Titers expressed as the reciprocal of the highest serum
dilution that gave optical density readings at least three-
fold higher than the mean of 10 naive cat sera and
samples that proved reactive at dilutions of 1:100 or
greater were considered positive. For the lymphoprolif-
eration assay, Ficoll-purified PBMC were incubated with
0.1 g of gradient-purified sonicated FIV-Pet grown in
FL-4 cells (Yamamoto et al., 1991) for 5 days, as de-
scribed (Matteucci et al., 1996). The stimulation index (SI)
was the ratio of radioactivity incorporated by PBMC in
the presence or absence of FIV antigen. Only SIs of 2
were considered indicative of FIV-specific lymphoprolif-
eration. Complete blood counts and differential leuko-
cyte counts were performed by standard methods. CD4
and CD8 T-lymphocyte counts were determined by flow
cytometry using a FACScan (BD Biosciences-Life Sci-
ence Research, Milan, Italy). The statistical significance
of the differences between groups was determined using
the Student’s unpaired t test assuming equal variances.
P values of less than 0.05 were considered significant.
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